• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
EXAS

EXAS

Exact Sciences Corporation

NASDAQHealthcareMedical - Diagnostics & ResearchUS

USD104.91

+0.00 (+0.00%)

Company Profile

CEO

Kevin T. Conroy

IPO Date

2001-02-01

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Exchange

NASDAQ

Country

US

Market Metrics

Open

$104.91

Prev. Close

$104.91

Day Low

$104.91

Day High

$104.91

52W Low

$38.81

52W High

$104.98

Market Cap

$20.03B

Volume

21.56M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

46.1%

Avg Negative

5.7%

Avg Neutral

48.3%

News Feed

Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan

PRNewsWire·8/16/2021·↑ positive

Clinical Gastroenterology and Hepatology Publishes Data Showing Exact Sciences' Oncoguard™ Liver Liquid Biopsy Test Delivers Enhanced Performance for Early-stage Detection of Hepatocellular Carcinoma

PRNewsWire·8/13/2021·↑ positive

Report: Exact Sciences (EXAS) Approached Invitae (NVTA) For Merger Offer

Pulse2·8/7/2021·↑ positive

Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top

Zacks Investment Research·7/29/2021·↑ positive

Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·7/28/2021·↓ negative

Exact Sciences Announces Second Quarter 2021 Results

PRNewsWire·7/28/2021·↑ positive

Bull of the Day: Exact Sciences (EXAS)

Zacks Investment Research·7/19/2021·↑ positive

Exact Sciences schedules second quarter 2021 earnings call

PRNewsWire·7/8/2021·↓ negative

Strong Revenue Trend Could Drive EXACT Sciences Corporation Stock To $160

Forbes·6/18/2021·↑ positive

Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research·6/3/2021·↓ negative